Leaders in Pharmaceutical Business Intelligence (LPBI) Group

1:15 -2:00 8/30 SELECTING PD-L1/PD-1 IMMUNOTHERAPY COMBINATIONS: Rational Combination Cancer Immunotherapy @IMMUNO-ONCOLOGY SUMMIT – AUGUST 30-31, 2016 | Marriott Long Wharf Hotel – Boston, MA

http://www.immuno-oncologysummit.com/uploadedFiles/Immuno_Oncology_Summit/Agenda/16/2016-The-Immuno-Oncology-Summit-Brochure.pdf

Leaders in Pharmaceutical Business intelligence (LPBI) Group covers in Real Time the IMMUNO-ONCOLOGY SUMMIT using Social Media

Aviva Lev-Ari, PhD, RN,

Founder, LPBI Group & Editor-in-Chief

http://pharmaceuticalintelligence.com

I attended a parallel session @ Marriott Long Wharf Hotel in Boston

Curation of Scientific Content @Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston

1:15 -2:00 8/30 SELECTING PD-L1/PD-1 IMMUNOTHERAPY COMBINATIONS: Rational Combination Cancer Immunotherapy

1:15 Chairperson’s Opening Remarks

Arthur M. Krieg, M.D. CEO, Checkmate Pharmaceuticals

1:20 KEYNOTE PRESENTATION: SELECTING PD-L1/PD-1 IMMUNOTHERAPY COMBINATIONS

Edward Cha, M.D., Ph.D., Associate Medical Director, Cancer Immunotherapy Franchise, Genentech Although targeted inhibition of the PD-L1 pathway enhances anti-tumor immunity, not all patients achieve benefit from single-agent immunotherapies. Determining and prioritizing effective combinations will rely on further understanding of the mechanisms that drive immune resistance across indications and individual patients.